68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT (original) (raw)

Abstract

Purpose-Investigating the value of 68 Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative 18 F-choline-PET/CT. Patients and Methods-One hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an 18 F-choline-PET/CT. If negative, an additional 68 Ga-PSMA-PET/CTwas offered. One hundred twenty-five of 139 eligible patients

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (42)

  1. Uchio EM, Aslan M, Wells CK, et al. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010; 170:1390-1395. [PubMed: 20696967]
  2. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59:572-583. [PubMed: 21315502]
  3. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014; 65:1034-1043. [PubMed: 23972524]
  4. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299:2760-2769. [PubMed: 18560003]
  5. Schiavina R, Ceci F, Borghesi M, et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm. 2013; 6:92-95. [PubMed: 23597246]
  6. Ceci F, Herrmann K, Castellucci P, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014; 41:2222-2231. [PubMed: 25182750]
  7. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35:18-23. [PubMed: 17891394]
  8. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013; 40(Suppl 1):S36-40. [PubMed: 23579864]
  9. Castellucci P, Ceci F, Graziani T, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 2014; 55:1424-1429. [PubMed: 24935990]
  10. Beer AJ, Eiber M, Souvatzoglou M, et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011; 12:181-191. [PubMed: 20599424]
  11. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3:81-85. [PubMed: 9815541]
  12. Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998; 83:2259-2269. [PubMed: 9840525]
  13. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998; 82:2256-2261. [PubMed: 9610707]
  14. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003; 9:6357- 6362. [PubMed: 14695135]
  15. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23:688-697. [PubMed: 22369515]
  16. Weineisen M, Simecek J, Schottelius M, et al. Synthesis and preclinical evaluation of DOTAGA- conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014; 4:63. [PubMed: 26116124]
  17. Ceci F, Uprimny C, Nilica B, et al. Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015; 42:1284-1294. [PubMed: 25975367]
  18. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:197-209. [PubMed: 25411132]
  19. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56:668- 674. [PubMed: 25791990]
  20. Weineisen M, Schottelius M, Simecek J, et al. Development and first in human evaluation of PSMA I&T-A ligand for diagnostic imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2014; 55:1083.
  21. Israel I, Richter D, Stritzker J, et al. PET imaging with [ 68 Ga]NOTA-RGD for prostate cancer: a comparative study with [ 18 F]fluorodeoxyglucose and [ 18 F]fluoroethylcholine. Curr Cancer Drug Targets. 2014; 14:371-379. [PubMed: 24720338]
  22. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591-1597. [PubMed: 10235151]
  23. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga- labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41:11-20. [PubMed: 24072344]
  24. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013; 40:486-495. [PubMed: 23179945]
  25. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with 11C-Choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. 2016; 43:55-69.
  26. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/ computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007; 100:786-793. [PubMed: 17822459]
  27. Rinnab L, Simon J, Hautmann RE, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009; 27:619-625. [PubMed: 19234708]
  28. Ceci F, Castellucci P, Graziani T, et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging. 2014; 41:878-886. [PubMed: 24346416]
  29. Brogsitter C, Zöphel K, Kotzerke J. 6-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging. 2013; 40(Suppl 1):S18-7. [PubMed: 23579863]
  30. Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014; 41:68-78. [PubMed: 24104592]
  31. Graute V, Jansen N, Ubleis C, et al. Relationship between PSA kinetics and [18 F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012; 39:271-282. [PubMed: 22086143]
  32. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 33C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1. 5 ng/ml? Eur J Nucl Med Mol Imaging. 2011; 38:55-63. [PubMed: 20848281]
  33. Mamede M, Ceci F, Castellucci P, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013; 38:e342-345. [PubMed: 23797218]
  34. Morigi JJ, Stricker P, Van Leeuwen P, et al. Prospective comparison of 18 F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015; 56:1185-90. [PubMed: 26112024]
  35. Velikyan I. Prospective of 68 Ga-radiopharmaceutical development. Theranostics. 2013; 4:47-80. [PubMed: 24396515]
  36. Herrmann K, Lapa C, Wester HJ, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015; 56:410-416. [PubMed: 25698782]
  37. Szabo Z, Mena E, Rowe SP, et al. Mol Imaging Biol. 2015:17-74.
  38. Malik N, Baur B, Winter G, et al. Radiofluorination of PSMA-HBED via AlF chelation and biological evaluations in vitro. Mol Imaging Biol. 2015:17-85.
  39. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA- HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17:575-84. [PubMed: 26013479] 68
  40. Ga-PSMA Positive, n in Choline- Negative Patients (%)
  41. - PSA indicates prostate-specific antigen; PSMA, prostate-specific membrane antigen;
  42. * PSA kinetics not available in 1 patient;